Significance of neurotransmitter abnormalities in Alzheimer's disease.
Katzman
R
R
Brown
T
T
Fuld
P
P
Thal
L
L
Davies
P
P
Terry
R
R
D000544:Alzheimer Disease / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D001921:Brain / Q000473:pathology*; D001923:Brain Chemistry; D002540:Cerebral Cortex / Q000032:analysis / Q000201:enzymology; D002766:Cholecystokinin / Q000032:analysis; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D006624:Hippocampus / Q000032:analysis; D006801:Humans; D009419:Nerve Tissue Proteins / Q000032:analysis; D009454:Neurofibrils / Q000473:pathology; D009478:Neuropeptide Y; D018377:Neurotransmitter Agents / Q000032:analysis*; D009638:Norepinephrine / Q000032:analysis; D011581:Psychological Tests; D014660:Vasoactive Intestinal Peptide / Q000032:analysis; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D009419:Nerve Tissue Proteins; D009478:Neuropeptide Y; D018377:Neurotransmitter Agents; D014660:Vasoactive Intestinal Peptide; D005680:gamma-Aminobutyric Acid; D002766:Cholecystokinin; D002795:Choline O-Acetyltransferase; D009638:Norepinephrine